Business
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential Phase 3 development program, with initial data expected in 2H 2026 TH103’s ongoing Phase 1a single ascending dose study remains on track for data to be reported in Q4 2025 PALO ALTO, Calif., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a
About this update from Kalaris Therapeutics, Inc.
[{"type":"image","alt":"Kalaris Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Kalaris Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":140,"height":40,"url":"https://media.zenfs.com/en/globenewswire.com/977835051d0e4fa1cb742bd1798bc7e3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HZjBrGjL._tUyizJOxV6og--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/977835051d0e4fa1cb742bd1798bc7e3","width":140,"height":40}},"lazy":false},{"type":"text","content":"Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial monthly doses of TH103","length":161,"tagName":"p"},{"type":"text","content":"Phase 1b/2 study to inform dose selection for potential Phase 3 development program, with initial data expected in 2H 2026","length":122,"tagName":"p"},{"type":"text","content":"TH103’s ongoing Phase 1a single ascending dose study remains on track for data to be reported in Q4 2025","length":109,"tagName":"p"},{"type":"text","content":"PALO ALTO, Calif., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it is now enrolling a Phase 1b/2 multiple ascending dose (MAD) study of TH103 in patients with neovascular age-related macular degeneration (nAMD). The study is intended to build upon the company's ongoing Phase 1a single ascending dose (SAD) study and represents a key advance in the clinical development program for TH103 towards potential Phase 3 clinical development. The new Phase 1b/2 dose-finding study is designed to evaluate multiple dose levels of TH103 in up to 80 nAMD patients. Patients will receive 4 initial monthly intravitreal injections of TH103. Study assessments are expected to include safety and preliminary efficacy with a primary time point for analysis at one-month following the last injection. Patients will then be followed in an extension phase of the study.","length":1061,"tagName":"p"},{"type":"text","content":"The Phase 1b/2 study replaces a smaller Part 2 design originally planned to follow the ongoing Phase 1a study. Data from the Phase 1a study, incl...